RT Journal Article
T1 Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.
A1 D'Avola, Delia
A1 Cuervas-Mons, Valentin
A1 Marti, Josep
A1 Ortiz-de-Urbina, Jorge
A1 Llado, Laura
A1 Jimenez, Carlos
A1 Otero, Esteban
A1 Suarez, Francisco
A1 Rodrigo, Juan M
A1 Gomez, Miguel-Angel
A1 Fraga, Enrique
A1 Lopez, Pedro
A1 Serrano, M Trinidad
A1 Rios, Antonio
A1 Fabrega, Emilio
A1 Herrero, Jose Ignacio
K1 Cardiovascular Diseases
K1 Cyclosporine
K1 Diabetes Mellitus, Type 1
K1 Dyslipidemias
K1 End Stage Liver Disease
AB Cardiovascular (CV) diseases are recognized longterm causes of death after liver transplantation (LT). The objective of this multicenter study was to analyze the prevalence and the evolution of CV risk factors and CV morbidity and mortality in 1819 LT recipients along 5 years after LT. The influence of baseline variables on survival, morbidity, and mortality was studied. There was a continuous and significant increase of the prevalence of all the CV risk factors (except smoking) after LT. CV diseases were the fourth cause of mortality in the 5 years after LT, causing 12% of deaths during the follow-up. Most CV events (39%) occurred in the first year after LT. Preexisting CV risk factors such as age, pre-LT CV events, diabetes, metabolic syndrome, and hyperuricemia, and mycophenolate-free immunosuppressive therapy, increased post-LT CV morbidity and mortality. The development of new-onset CV risk factors after LT, such as dyslipidemia and obesity, independently affected late CV morbidity and mortality. Tacrolimus and steroids increased the risk of posttransplant diabetes, whereas cyclosporine increased the risk of arterial hypertension, dyslipidemia, and metabolic syndrome. In conclusion, CV complications and CV mortality are frequent in LT recipients. Preexisting CV risk factors, immunosuppressive drugs, but also the early new onset of obesity and dyslipidemia after LT play an important role on late CV complications. A strict metabolic control in the immediate post-LT period is advisable for improving CV risk of LT recipients. Liver Transplantation 23 498-509 2017 AASLD.
PB Wolters Kluwer Health
YR 2017
FD 2017-03-27
LK http://hdl.handle.net/10668/10839
UL http://hdl.handle.net/10668/10839
LA en
NO D'Avola D, Cuervas-Mons V, Martí J, Ortiz de Urbina J, Lladó L, Jimenez C, et al.  Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil. Liver Transpl. 2017 Apr;23(4):498-509
DS RISalud
RD Apr 7, 2025